Moving beyond trial and error in drug development
The Generate Platform infers generalizable principles of biology from at-scale observations to deliberately generate medicines towards treating humanity’s most intractable diseases.
Our platform upends the traditional drug development process and represents a fundamental shift in therapeutic development.
The Generate Platform–which is a continuous loop to generate, build, measure, and learn–can drastically increase the speed at which therapeutics are identified and validated.
Generate
Best-in-class algorithms generate protein sequences to answer a specific therapeutic question.
Build
Computationally generated sequences are created as real proteins at scale.
Measure
Next-generation systems measure critical molecular characteristics and functions of our generated proteins.
Learn
High quality data, generated at scale, drive the improvement in our engine, and every molecule we generate.
Generating de novo protein-protein interactions.
Machine learning models can generate protein complexes of any variety, including antibodies that target defined epitopes and functional antibodies that agonize cell surface receptors.
Applying AI to transform drug discovery.
GB-0895 is an example of how generative AI can be applied with precision and purpose—designed to block TSLP, a key initiator of the inflammatory cascade in asthma, and co-optimized from the start for both biological effect and patient experience. Built to extend half-life, improve potency, and reduce dosing frequency, GB-0895 has the potential to shift treatment from monthly to just twice per year.
Proteins that are invisible to the immune system.
The Generate Platform enables us to completely recode a therapeutic protein to retain function while reducing or eliminating recognition by the immune system.